Arrhythmias & electrophysiology

Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

EuropacePublished Retrospective cohort study

Main finding · Cardiac eventsResult — go to the resultHazard ratio 0.34 CI 0.22–0.54

Authors' conclusion

Heterozygous carriers of JLNS variants have a lower risk of cardiac arrhythmic events than other LQT1 patients.

Study context

Population
LQT1 or Jervell and Lange-Nielsen syndrome (JLNS) patients with class IV/V KCNQ1 variants, September 1993 to January 2023KCNQ1 variant carriers
Participants
789 participants
Exposure
HTZ-JLNS vs HTZ-Non-JLNS
  • JLNSn = 30
  • HTZ-JLNSn = 161
  • HTZ-Non-JLNSn = 550reference
Outcome
QTc duration and incidence of long QT syndrome-related cardiac events
Methodological detailssingle-centre inherited arrhythmia clinic, literature review for JLNS variants
  • Single-centre inherited arrhythmia clinic
  • Literature review for JLNS variants

Main finding

Cardiac events

Hazard ratio

0.34

CI 0.22–0.54

P < 0.01

HTZ-JLNS vs HTZ-Non-JLNS
HR 0.34 (CI 0.22–0.54); P < 0.01

As reported in the abstract

Observational data: associations, not effects.

Further findings

QTc at diagnosis

Genetic parameters independently associated with cardiac events (multivariate analysis)

ComparisonHR (CI)P value
HaploinsufficiencyMultivariate Cox regression0.60 (0.37–0.97)P = 0.04
C-terminal localizationMultivariate Cox regression0.67 (0.46–0.98)P = 0.04
GroupMultivariate Cox regression0.43 (0.27–0.69)P < 0.01
OutcomeHRP value
Genetic parameters independently associated with cardiac events (multivariate analysis)Pore localization · upper CI limit misprinted in abstract · multivariate Cox regression1.61P < 0.01

Original publication

Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients. Europace. Published 3 June 2024. doi:10.1093/europace/euae136

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.